TGFB1 and mesothelioma: Our group previously reported similar anti-tumor effects after administering a soluble type II TGF-β receptor (sTGF-βR) that binds and neutralizes TGF-β1 and TGF-β3 in a murine model of established mesothelioma tumors (Figure 1).